ABBV

Abbvie Inc

288.01

Nov 02 • 1:08 PM ET -6.88 (-2.33%)

Healthcare Drug Manufacturers - General USA Mega NYSE

Oct 30, 11:34 AMAbbVie beats Q3 2026 guidance with EPS $3.82 and revenue $17.4B, raises 2026 outlook and dividend 5.2%

Peers: JNJ MRK AMGN LLY NVS BMY PFE AZN GILD NVO

| Held by: VTI VOO IVV SPY VTV XLV VIG VYM VHT SPYM

Scroll to Statements

Index	S&P 500
Market Cap	508.95B
Enterprise Value	573.25B
Income	10.31B
Sales	66.01B
Book/sh	-3.36
Cash/sh	3.72
Dividend Est.	6.85 (2.38%)
Dividend TTM	6.92 (2.40%)
Dividend Ex-Date	Jan 15, 2027
Dividend Gr. 3/5Y	5.21% 6.56%
Payout	281.66%
Employees	57000
IPO	Dec 10, 2012

P/E	49.51
Forward P/E	17.70
PEG	0.82
P/S	7.71
P/B	-
P/C	77.48
P/FCF	27.95
EV/EBITDA	19.16
EV/Sales	8.68
Quick Ratio	0.69
Current Ratio	0.81
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	5.82
EPS next Y	16.28
EPS next Q	3.89
EPS this Y	39.59%
EPS next Y	16.60%
EPS next 5Y	21.62%
EPS past 3/5Y	-29.11% -2.81%
Sales past 3/5Y	1.75% 5.95%
EPS Y/Y TTM	68.16%
Sales Y/Y TTM	10.68%
EPS Q/Q	2297.18%
Sales Q/Q	10.32%
Earnings	Oct 30 BMO
EPS/Sales Surpr.	2.51% 0.51%

Insider Own	-
Insider Trans	-
Inst Own	78.32%
Inst Trans	0.44%
ROA	4.60%
ROE	15221.82%
ROIC	18.24%
Gross Margin	85.07%
Oper. Margin	36.22%
Profit Margin	15.62%
SMA20	1.86%
SMA50	6.77%
SMA200	21.29%
Trades

Shs Outstand	1.77B
Shs Float	1.77B
Short Float	0.88%
Short Ratio	3.27
Short Interest	15.58M
52W High	298.74 -3.59%
52W Low	190.75 50.99%
Volatility	2.00% 2.41%
ATR (14)	6.57
RSI (14)	60.77
Beta	0.19
Rel Volume	1.43
Avg Volume	4.76M
Volume	3,950,701

Perf Week	0.44%
Perf Month	9.59%
Perf Quarter	18.13%
Perf Half Y	38.36%
Perf YTD	26.05%
Perf Year	32.09%
Perf 3Y	101.04%
Perf 5Y	147.16%
Perf 10Y	407.15%
Recom	1.62
Target Price	308.58
Prev Close	294.89
Price	288.01
Change %	-2.33%

Consensus

Buy

Avg. Price Target

$308.58

Implied Upside

+7.1%

Analysts15incl. previous ratings

Rating Distribution12 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 13, 2026	Upgrade	WWolfe Research	Peer Perform → Outperform	$300	+4.2%
Aug 05, 2026	Upgrade	EErste Group	Hold → Buy
Apr 30, 2026	Upgrade	BBofA Securities	Neutral → Buy	$234	-18.8%
Apr 21, 2026	Initiated	CCanaccord Genuity	Buy	$262	-9.0%
Feb 25, 2026	Initiated	RRBC Capital Mkts	Outperform	$260	-9.7%
Feb 20, 2026	Initiated	BBarclays	Overweight	$275	-4.5%
Jan 08, 2026	Downgrade	WWolfe Research	Outperform → Peer Perform
Jan 07, 2026	Resumed	UUBS	Neutral	$240	-16.7%
Dec 10, 2025	Upgrade	HHSBC Securities	Hold → Buy	$265	-8.0%
Nov 13, 2025	Initiated	BScotiabank	Sector Outperform	$280	-2.8%
Nov 04, 2025	Downgrade	DDZ Bank	Buy → Hold	$237	-17.7%
Oct 14, 2025	Downgrade	EErste Group	Buy → Hold
Oct 01, 2025	Downgrade	HHSBC Securities	Buy → Hold
Sep 17, 2025	Upgrade	BBerenberg	Hold → Buy	$270	-6.3%
Aug 12, 2025	Resumed	PPiper Sandler	Overweight	$231	-19.8%
Aug 07, 2025	Upgrade	DDaiwa Securities	Neutral → Outperform	$214	-25.7%
May 14, 2025	Downgrade	CCitigroup	Buy → Neutral	$205	-28.8%
Apr 22, 2025	Initiated	CCantor Fitzgerald	Overweight	$210	-27.1%
Dec 10, 2024	Resumed	BBofA Securities	Neutral	$191	-33.7%
Dec 05, 2024	Downgrade	DDaiwa Securities	Outperform → Neutral	$180	-37.5%

Oct-30-26 03:13PM	LLY, ABBV Stocks Hit All-Time High Heres Whats Driving Investor Enthusiasm Today (Stocktwits)
02:22PM	AbbVie Beats And Effectively Absorbs Its IPR&D Charge, But Skyrizi's Slowdown Tests A Stock Priced At Its Highs (Earnings Whispers)
01:13PM	The big winners of the tech wreck are biopharma stocks (MarketWatch)
09:44AM	Pre-Markets Spooked on Questions Regarding AI, Oil Prices (Zacks)
08:51AM	AbbVie's Earnings Double As Immunology Powerhouse Skyrizi Beats Again (Investor's Business Daily)
08:25AM	Loading…
08:25AM	AbbVie beats estimates but stock dips (Investing.com)
08:00AM	AbbVie Revenue Rises on Strength in Immunology, Neuroscience (The Wall Street Journal)
07:54AM	AbbVie: Q3 Earnings Snapshot (Associated Press)
07:46AM	AbbVie Reports Third-Quarter 2026 Financial Results (PR Newswire)
Oct-28-26 01:21PM	Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50% (Barrons.com)
08:00AM	The Countdown Is On: BOTOX Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18 (PR Newswire)
Oct-27-26 08:45AM	Healthcare Stocks Become Anti-AI Bet as Investors Turn Defensive (Bloomberg)
08:30AM	Allergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX Cosmetic (onabotulinumtoxinA) (PR Newswire)
08:00AM	AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma (PR Newswire)
03:14AM	IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A Very Good Spec Amid Biotech Takeover Wave (Stocktwits)
08:00AM	Loading…
Oct-26-26 08:00AM	Allergan Aesthetics Celebrates Eight Years of Engaging Girls in STEM Through Continued Partnership with Girls Inc. (PR Newswire)
Oct-23-26 03:33PM	U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease (PR Newswire)
07:39AM	AbbVies skin disease drug posts Phase III win as market competition heats up (Clinical Trials Arena)
Oct-22-26 09:00AM	AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa (PR Newswire)
07:25AM	AbbVie Faces A Street Forecast Above Its Own Guidance As Immunology Momentum Meets Apogee Dilution (Earnings Whispers)
Oct-21-26 08:00AM	Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa Evidence (PR Newswire)
07:40AM	AbbVie races into F1 as pharma companies continue push into sport (Pharmaceutical Technology)
Oct-20-26 04:28PM	Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Rises (Investor's Business Daily)
02:53PM	Wall Street rises with investors rotating into healthcare and value stocks (Reuters)
07:55AM	AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community (PR Newswire)
Oct-19-26 04:00AM	AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-a4ß7 Monotherapy in Moderate to Severe Crohn's Disease (PR Newswire)
Oct-18-26 06:10PM	AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio (PR Newswire)
Oct-17-26 02:00AM	SKYRIZI (risankizumab) and RINVOQ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 (PR Newswire)
Oct-16-26 10:57PM	What Was Eli Lilly Telling You Before Its Stock Ran? (Trefis)
08:53PM	When Amgen's Forecast And Chart Say The Same Thing, Pay Attention (Trefis)
08:37PM	Loading…
08:37PM	Gileads HIV Prevention Business Just Topped $1 Billion A Quarter. What Comes Next? (Trefis)
08:13PM	Is Amgen Stock Increasing Your Market Risk? (Trefis)
02:24PM	AbbVie or Altria: The One Dividend Stock Id Hold for the Next 10 Years (TIKR)
10:57AM	5 Stock Ideas for Your Short List (Zacks)
Oct-15-26 03:46PM	How Has Merck's Story Changed? (Trefis)
03:36PM	Healthcare Stocks Are on a Tear. Gilead and AbbVie Are Heading for Record Highs. (Barrons.com)
02:25PM	Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets (MarketWatch)
01:38PM	Cathie Wood-Backed Biotech IPO Pops in Debut (Barrons.com)
09:09AM	Where Could Johnson & Johnson's Next Growth Come From? (Trefis)
Oct-14-26 10:02PM	Why Eli Lilly Became Wall Streets Safe Haven on a Hot CPI Day (TIKR)
05:45PM	What Could Send Regeneron Stock Higher? (Trefis)
11:13AM	Tech stocks take a back seat as healthcare names steal the show (MarketWatch)
08:18AM	The Open Question Under Johnson & Johnson Stock's Price (Trefis)
Oct-13-26 07:48PM	Is Amgen Stock Worth More Than Its Competitors? (Trefis)
03:59PM	What Does Bristol-Myers Squibb Offer That Pfizer Does Not? (Trefis)
03:24PM	What Is Eli Lilly Stock's Biggest Opportunity? (Trefis)
03:15PM	AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease (PR Newswire)
Oct-11-26 09:22PM	SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH (Stocktwits)
01:00PM	New SKYRIZI (risankizumab-rzaa) and RINVOQ (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease (PR Newswire)
Oct-09-26 08:47PM	Why Is Everyone Ignoring Gilead Stock's High Cash Yield? (Trefis)
02:12PM	Does The Move In Merck Stock Change Anything? (Trefis)
Oct-08-26 08:36PM	Should You Be Worried About Pfizer Stock? (Trefis)
08:19PM	What Is Going On With Regeneron Stock? (Trefis)
09:03AM	What Would It Take For Amgen Stock To Move Higher? (Trefis)
09:00AM	Pharmas $500B patent problem will come in waves not as a cliff (Pharma Voice)
Oct-07-26 12:13PM	Why You Should Think About Eli Lilly Stock Differently Now (Trefis)
09:09AM	Micro-Cap Stock Veraxa Biotech Is Down 96% This Year. Can Next-Gen Drug Testing Save It? (Barrons.com)
08:30AM	AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC (PR Newswire)
Oct-06-26 12:46PM	European shares rise as retreating bond yields and oil prices boost risk appetite (Reuters)
11:42AM	Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial (BioPharma Dive)
04:35AM	Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug (The Wall Street Journal)
03:52AM	Genmab jumps as its lymphoma drug combo with AbbVie cuts progression, death risk (Investing.com)
Oct-05-26 04:48PM	AbbVie Partner Flies Sky-High On News For Its $3 Billion Cancer Contender (Investor's Business Daily)
03:29PM	Genmab stock surges 11% on positive cancer drug trial data (Investing.com)
03:03PM	Better Dividend for Retirees: AbbVie vs. Merck (TIKR)
02:54PM	AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (PR Newswire)
02:50PM	Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (Business Wire)
10:19AM	Has Eli Lilly Stock Peaked? (Trefis)
04:08AM	AbbVie Announced Its 340B Rebate Pilot on October 2. Heres What It Means for the Stock Before Vraylars 2027 Medicare Price Cut (TIKR)
Oct-02-26 05:40PM	How to Create a Million-Dollar Stock Portfolio (Zacks)
06:27AM	How Has Pfizer's Story Changed? (Trefis)
Oct-01-26 12:16PM	3 takeaways from a European obesity scientific meeting (BioPharma Dive)
11:41AM	What Is The Options Market Telling Us About Eli Lilly Stock? (Trefis)
10:00AM	AbbVie Presents Long-Term RINVOQ (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo (PR Newswire)
08:00AM	AbbVie to Host Third-Quarter 2026 Earnings Conference Call (PR Newswire)
Sep-30-26 03:01PM	Was The Run In JNJ Stock Hiding In Plain Sight? (Trefis)
11:29AM	Are You Overpaying For Pfizer Stock Versus Its Rivals? (Trefis)
10:43AM	What Is Merck Stock's Biggest Opportunity? (Trefis)
10:18AM	PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval (BioPharma Dive)
05:45AM	AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026 (PR Newswire)
01:30AM	AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 (PR Newswire)
01:00AM	AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress (PR Newswire)
Sep-29-26 02:57PM	Defensive Dividends: 3 Companies Investors Can Rely On (Zacks)
02:43PM	Is Eli Lilly Stock a Good Fit For Your Portfolio Risk? (Trefis)
12:23PM	Management Raised the Bar For Eli Lilly Stock; Does The Chart Agree? (Trefis)
12:19PM	AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval (GuruFocus.com)
09:00AM	AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development (PR Newswire)
Sep-28-26 04:33PM	$85 Billion And Counting: JNJ Stock's Steady Cash-Return Habit (Trefis)
03:49PM	Top Research Reports for Alphabet, Mastercard & AbbVie (Zacks)
02:08PM	What Are Merck Stock Investors Overlooking? (Trefis)
11:14AM	AbbVie Won FDA Approval for Parkinsons Pill Juvmo. Heres Why Management Already Expects a Slow Start (TIKR)
11:08AM	AbbVie Just Won an FDA First in Parkinson's Disease (GuruFocus.com)
09:54AM	AbbVie Receives FDA Approval for Parkinson's Disease Drug Juvmo (InvestorsHub)
08:00AM	U.S. FDA Approves AbbVie's JUVMO (tavapadon) for Parkinson's Disease (PR Newswire)
Sep-25-26 09:02PM	Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines (Stocktwits)
01:13PM	Is LLY Stock Cheaper Than It Looks? (Trefis)
01:03PM	Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money? (Trefis)
10:06AM	ADARx Pharmaceuticals raises $446 million in upsized IPO (Quartz)
05:30AM	The Peptide Boom That Isn't About Your Muscles (The Wall Street Journal)
Sep-24-26 08:36PM	RNAi drug specialist ADARx raises $446M IPO (BioPharma Dive)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Aug 14 '26	Option Exercise	79.02	32,710	2,584,744	107,140	Aug 18 05:00 PM
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Aug 14 '26	Sale	250.00	32,710	8,177,500	74,430	Aug 18 05:00 PM
NICHOLAS DONOGHOE	Officer	Aug 14 '26	Proposed Sale	250.00	32,710	8,177,500		Aug 14 04:36 PM
ROBERT J ALPERN	Director	May 26 '26	Proposed Sale	214.00	13,000	2,781,991		May 26 04:10 PM
Purdue David Ryan	SVP, Controller	Mar 04 '26	Sale	233.56	5,230	1,221,519	2,654	Mar 06 05:05 PM
David R. Purdue	Officer	Mar 04 '26	Proposed Sale	233.56	5,230	1,221,519		Mar 06 05:04 PM
Siatis Perry C	EVP, GC AND SECRETARY	Mar 02 '26	Sale	234.39	18,668	4,375,549	4,619	Mar 03 06:10 PM
PERRY C SIATIS	Officer	Mar 02 '26	Proposed Sale	234.39	18,668	4,375,585		Mar 02 04:05 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 25 '26	Option Exercise	172.62	22,381	3,863,458	60,518	Feb 27 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 25 '26	Sale	230.00	22,381	5,147,630	38,137	Feb 27 05:00 PM
PERRY C SIATIS	Officer	Feb 25 '26	Proposed Sale	230.00	22,381	5,147,630		Feb 25 04:49 PM

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson's disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

CEO & Chairman of the BoardMr. Robert A. Michael CPA

Executive VP & CFOMr. Scott T. Reents

Executive VP & COODr. Azita Saleki Ph.D.

Executive VP of Research & Development and Chief Scientific OfficerDr. Roopal B. Thakkar M.D.

Executive VP & Chief Commercial OfficerMr. Jeffrey Ryan Stewart

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABBV

Abbvie Inc

Upgrade your Finviz experience